biopharmaceutical

Totus Medicines is a biopharmaceutical company developing precision oral medicines against historically "undruggable" disease targets. The company's OmniDEL discovery platform screens targets in their normal cellular environment to identify potent, selective covalent small molecules, drawing on precedents like penicillin and AZT.

Seismic Therapeutic is a clinical-stage biopharmaceutical company developing transformative biologic medicines for autoimmune and inflammatory diseases. The company pairs structural biology with machine learning through its proprietary IMPACT platform to design multi-functional antibodies and Immunoglobulin Sculpting (IgSc) enzymes across…

Braveheart Bio is a late clinical-stage biopharmaceutical company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiac conditions. Its lead candidate, BHB-1893, is a selective cardiac myosin inhibitor (licensed as HRS-1893 from Hengrui Pharma) designed to reduce excessive heart-muscle contraction and improve…

Nocion Therapeutics is a clinical-stage biopharmaceutical company discovering and developing a novel class of biologically selective charged sodium channel (NaV) blockers designed to selectively silence overactive sensory neurons to relieve chronic cough, pain, itch, and inflammation.

Sciwind Biosciences (Hangzhou Sciwind Biosciences Co., Ltd.) is a commercial-stage biopharmaceutical company headquartered in Hangzhou, China, with a US office in San Ramon, California, focused on discovering, developing, and delivering innovative therapeutics for weight management and metabolic disease.

Granata Bio is a reproductive-health biopharmaceutical company founded in 2018 and headquartered in the United States, focused on expanding access to fertility and IVF therapeutics across North America.

Shanghai Vitalgen BioPharma Co., Ltd. (Vitalgen), founded in March 2020 and headquartered in Shanghai, China, translates cutting-edge gene delivery and gene editing techniques into clinically effective treatments for patients with unmet medical needs.

Metsera is a clinical-stage biopharmaceutical company developing injectable and oral therapies for obesity and metabolic diseases, backed by GV and the SoftBank Vision Fund. As of this enrichment pass its corporate domain (metsera.com) issues a 301 redirect to pfizer.com, consistent with Metsera's acquisition by Pfizer.

ArriVent BioPharma (NASDAQ: AVBP) is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines for the treatment of cancer.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapies for underserved areas of medical need. Leveraging a proprietary integrin drug discovery and delivery platform, its lead program PLN-101095 is a dual-selective avb8/avb1 integrin inhibitor being evaluated in the…

Semnur Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing non-opioid pain-management therapies. Its lead program, SP-102 (SEMDEXA), is a novel, non-opioid, preservative-free and particulate-free injectable corticosteroid gel formulation intended to treat moderate-to-severe chronic radicular pain (sciatica).

Novamab (洛启生物) is a Shanghai-based clinical-stage biopharmaceutical company specializing in VHH (nanobody) antibody drug development for respiratory and inflammatory diseases such as asthma, COPD, and IBD.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Newark, California and founded in 2006. It discovers and develops peptide-based new chemical entities using a proprietary peptide discovery and engineering platform, targeting rare and prevalent diseases with significant unmet medical need.

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule and biologic therapeutics for autoimmune, inflammatory, and oncology indications. The company targets upstream immune signaling mechanisms to prevent pathological inflammation rather than only suppressing downstream responses, advancing a pipeline of…

Ark Biopharmaceutical (爱科百发, Ark Biosciences) is a Shanghai-based clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for respiratory diseases and pediatric conditions.

Millennium Pharmaceuticals was a biopharmaceutical company based in Cambridge, Massachusetts, focused on oncology and inflammation, best known for developing the cancer drug Velcade (bortezomib).

CREATE Medicines is a Cambridge, Massachusetts biopharmaceutical company developing in vivo CAR (chimeric antigen receptor) cell therapies using mRNA lipid-nanoparticle (mRNA-LNP) delivery.

Axcelius I/II is a biopharmaceutical company-creation vehicle backed by Canaan Partners, formed to found and incubate drug-development companies pursuing treatments for cancer, rare diseases, and neurodegenerative disorders.

Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to guide and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic viral infection, and cancer.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.